Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Asthma, abbreviation for bronchial asthma, is one of the common chronic airways disease that threatens human health. Typical symptoms of asthma are recurrent wheezing, shortness of breath, chest tightness and cough, usually occurring at night or early morning. However, there are still some patients with only persistent clinical manifestations of chest tightness. Concerned about this group of patients, we presented a subgroup of bronchial asthma, namely, chest tightness variant asthma (CTVA). This asthma subgroup usually lacks asthma-specific clinical features such as wheezing, shortness of breath, wheezing, and therefore often misdiagnosed for a long time. In order to further understand the clinical characteristics, pathogenesis, and prognosis of patients with CTVA, we conducted a national multicenter observation study to further understand CTVA. Finally, we plan to clarify whether CTVA is a relatively independent asthma phenotype. Meanwhile, reducing misdiagnosis and perform an appropriate treatment of CTVA.
Condition or disease
AsthmaChest SyndromeClinical AnxietyClinical DepressionLung FunctionQuality of LifeEosinophiliaNitric OxideAirway ResponsivenessInduced Sputum
Drug: Treat patient according to Global Initiative for Asthma (GINA) guideline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
14 Years to 80 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with only symptom of chest tightness and bronchial provocation test positive according to eligibility criteria.
all subjects agreed to participate, understand the project, observe the use of drugs, agree to follow-up, and signed informed consent;
the age of more than 14 and less 80 years old, gender and ethnicity are not limited;
the duration time was more than 6 months,and chest tightness was the only complaint, without breathing, short of breath, chronic cough;
a diagnosis of asthma supported by one or more other characteristics:
bronchial provocation test positive;
improvement in forced expiratory volume at one second (FEV1) of more than 12% and 200 mL after inhaled salbutamol;
variability in diurnal peak expiratory flow (PEF) of more than 10% for one day during one week.
bronchodilator and glucocorticoid treatment is effective;
exclude the following diseases by the corresponding doctors: coronary heart disease, myocarditis, heart failure, GERD, neuromuscular disease, and mental disease.
can not cooperate with related inspection or for other reasons;
patients with chronic obstructive pulmonary disease, interstitial pneumonia, active tuberculosis, community acquired pneumonia, lung cancer, bronchiectasis, cor pulmonale, pulmonary embolism, and accompanied with serious systematic disease (such as coronary heart disease, myocarditis, heart failure, gastroesophageal reflux disease, neuromuscular disease, etc);
history of drug abuse, alcohol abuse or anesthesia or with a history of mental illness (schizophrenia, obsessive-compulsive disorder, depression) and against personality, motivation, suspicious, or other emotional or mental issues that may affect participation in the study;
taking part in other drug clinical trial project, or drop out less than 3 months;